Pfizer’s $43 Billion Gamble: Betting Big on Turbo Cancer Treatments Despite Red Flags

Pfizer’s $43 Billion Gamble: Betting Big on Turbo Cancer Treatments Despite Red Flags: Pfizer has made a jaw-dropping move in the medical industry, finalizing the purchase of Seagen, a modest-sized drug company known for its innovative treatments for aggressive cancers, in a deal valued at a whopping $43 billion. Despite Seagen's relatively modest annual revenue of $2 billion, Pfizer's acquisition signals a major play to expand its oncology portfolio and solidify its position in the market.